-
- Barton F. Haynes
- Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
-
- Lawrence Corey
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA.
-
- Prabhavathi Fernandes
- Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland.
-
- Peter B. Gilbert
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research, Washington, Seattle, WA 98109, USA.
-
- Peter J. Hotez
- Texas Children’s Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
-
- Srinivas Rao
- Sanofi Research and Development, Sanofi, Cambridge, MA 02139, USA.
-
- Michael R. Santos
- Foundation for the National Institutes of Health, North Bethesda, MD 20852, USA.
-
- Hanneke Schuitemaker
- Janssen Vaccines & Prevention B.V., Leiden, Netherlands.
-
- Michael Watson
- Moderna Inc., Cambridge, MA 02139, USA.
-
- Ann Arvin
- Departments of Pediatrics and Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
抄録
<jats:p>Prior vaccine development experiences do not raise concerns about vaccine-associated enhanced disease for COVID-19 vaccine candidates.</jats:p>
収録刊行物
-
- Science Translational Medicine
-
Science Translational Medicine 12 (568), 2020-11-04
American Association for the Advancement of Science (AAAS)